Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp215 | Cell biology: osteoclasts and bone resorption | ECTS2013

The F-actin modulator SWAP-70 is required for proper podosome dynamics in osteoclasts

Roscher Anne , Glosmann Martin , Reinhold G Erben , Lutter Anne-Helen , Chopin Michael , Lorenz C Hofbauer , Jessberger Rolf , Garbe Annette

Bone remodeling is a crucial process to maintain a healthy bone structure in order to avoid diseases like osteoporosis or osteopetrosis. Osteoclasts contribute to this process by resorbing old and brittle bone allowing osteoblasts to renew the bone substance. During resorption osteoclasts rearrange their actin cytoskeleton by forming an F-actin ring generating a resorptive cavity on the bone surface. Recently, we reported that the F-actin binding protein SWAP-70 regulates oste...

ba0002p97 | (1) | ICCBH2013

Vitamin D status and bone health in survivors of childhood lymphoblastic leukemia

Schundeln Michael M , Hauffa Pia K , Goretzki Sara C , Lahner Harald , Marschke Laura , Eggert Angelika , Hauffa Berthold P , Grasemann Corinna

Introduction: Lymphoblastic leukemia is the predominant form of childhood malignancies with survival rates of >80%. Late effects of cancer and treatment can affect endocrine function and may account for acute and chronic impairment of bone health.Aim and design: To assess bone health in pediatric patients after therapy for lymphoblastic leukemia we initiated a clinical trial investigating clinical and biochemical parameters of growth, puberty, bone t...

ba0002p98 | (1) | ICCBH2013

Effects of denosumab on bone biochemistry and calcium metabolism in a girl with Juvenile Paget’s disease

Grasemann Corinna , Schundeln Michael , Wieland Regina , Bergmann Christoph , Wieczorek Dagmar , Zabel Bernhard , Schweiger Bernd , Hauffa Berthold P

Juvenile Paget’s disease (JPD) is an extremely rare, yet painful and debilitating bone disease with onset occurring during early childhood. JPD can be caused by loss of function of osteoprotegerin, resulting in subsequent osteoclast stimulation via the activated receptor activator of nuclear factor-kappa B (RANK) pathway. Increased bone turnover and a lack of bone modelling lead to severe deformities, frequent fractures, short stature and loss of hearing.<p class="abs...

ba0003pp18 | Bone biomechanics and quality | ECTS2014

Influence of PTH treatment on the bone tissue mechanics of rats with type 2 diabetes mellitus using mechanical tests and finite element modelling

Campbell Graeme , Hamann Christine , Picke Ann-Kristin , Rauner Martina , Huber Gerd , Morlock Michael , Hofbauer Lorenz , Gluer Claus-Christian

Diabetes mellitus results in increased skeletal fragility through reduced bone mineral density and altered collagen structure. How these changes affect bone mechanics at the tissue level remains largely unclear. Anti-osteoporosis medications improve bone mass, but whether they can fully restore tissue strength in diabetic bone, where collagen quality is compromised, has not been fully elucidated. The objective of this study was to determine the effect of type 2 diabetes mellit...

ba0003pp92 | Bone development/growth and fracture repair | ECTS2014

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

Bilezikian John P , Maruani Gerard , Rothman Jeffrey , Clarke Bart L , Mannstadt Michael , Vokes Tamara , Lagast Hjalmar , Shoback Dolores M

Hypoparathyroidism results in low bone turnover and increased bone mineral density (BMD). Replacing deficient PTH with rhPTH(1–84) has the potential to correct these skeletal abnormalities. To investigate the effect of rhPTH(1–84) on BMD and bone turnover markers (BTMs), data from two studies were assessed.REPLACE, a double-blind, multicenter, placebo-controlled study, randomized 134 patients with hypoparathyroidism to receive once-daily rhPTH(...

ba0003pp173 | Cell biology: osteoclasts and bone resorption | ECTS2014

Inhibition of bone remodeling by bisphosphonate displaces the plasma cell niche into the spleen

Teufel Stefan , Grotsch Bettina , Luther Julia , Schinke Thorsten , Amling Michael , Schett Georg , Mielenz Dirk , David Jean-Pierre

Bone marrow is the main hematopoietic organ of adults. There, hematopoietic stem cells from which all hematopoietic lineages can be generated are preferentially homing. Importantly, bone provides niches for early B cell differentiation and survival of long-lived plasma cells that produced antibodies. Thus, that perturbing bone homeostasis might impact B cell function and antibody production is a highly relevant hypothesis for patients receiving antiresorptive drugs.<p clas...

ba0003pp355 | Osteoporosis: treatment | ECTS2014

Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment

Ominsky Michael S , Libanati Cesar , Boyce Rogely , Kostenuik Paul J , Baron Roland , Wagman Rachel B , Dempster David W

In clinical studies, denosumab (DMAb) administration up to 8 years is associated with continued increases in bone mineral density (BMD) and low fracture incidence despite persistently low bone turnover markers and limited iliac crest tetracycline labelling (Papapoulos 2013). We tested the hypothesis that, with persistently low bone remodelling, BMD increases may result from a non-remodelling dependent mechanism to accrue bone matrix. We examined the fluorochrome labelling patt...